News
05-19-2011, 12:20 AM
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
More... (http://www.news-medical.net/news/20110519/Silence-to-present-new-Atu027-Phase-I-study-data-in-advanced-solid-tumors-at-ASCO-annual-meeting.aspx)
More... (http://www.news-medical.net/news/20110519/Silence-to-present-new-Atu027-Phase-I-study-data-in-advanced-solid-tumors-at-ASCO-annual-meeting.aspx)